Imatinib mesylate (Gleevec) binds BCR-ABL and c-KIT, and is an effective treatment for BCR-ABL+ chronic myeloid leukemia. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.